Brief: AB Science Receives NOD From Health Canada For Masitinib
13/12/2022 17:18
Dec 13 (Reuters) - AB Science SA ABS.PA :
* AB SCIENCE RECEIVES NOTICE OF DEFICIENCY (NOD) FROM HEALTH
CANADA FOR MASITINIB IN THE TREATMENT OF AMYOTROPHIC LATERAL
SCLEROSIS (ALS)
* AB SCIENCE WILL LIAISE WITH HEALTH CANADA TO ADDRESS
DEFICIENCIES, WITH INTENTION TO RESUME PROCESS WITHIN ALLOCATED
TIMEFRAME
Source text for Eikon: ID:nGNX7wf87V
Further company coverage: ABS.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on AB Science SA
See all newsBrief: AB Science Expects To Resume AB8939 Phase 1 In Q1 2027 And Masitinib Phase 3 In Q4 2027
Brief: AB Science Discontinues Phase 2 AB20006, Phase 3 AB15003, Phase 3 AB20009 Studies
Brief: AB Science Temporarily Halts Europe Clinical Trials Ahead Of Strategic Reorganization
Brief: AB Science Says FDA Granted Status Of Minor Use In Major Species For Masivet
Brief: AB Science Says Co Received Japanese Patent Protection To Use Masitinib In Progressive MS Until 2041